Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on Wave Life Sciences (WVE – Research Report) and increased the price target ...

Wave's RNA editing technology appears to have highly potential for the treatment of AATD, a genetic disorder with potential ...

Fintel reports that on October 16, 2024, Raymond James upgraded their outlook for Wave Life Sciences (NasdaqGM:WVE) from ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is ...

US RNA medicines biotech Wave Life Sciences yesterday announced positive proof-of-mechanism data from the ongoing Phase ...

RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...

Wave Life Sciences reports that it has successfully carried out RNA editing in two patients with alpha-1 antitrypsin ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

The Australian has published its fourth annual edition of The List – Top 100 Innovators 2024: The Next Wave. Identifying the ...

Covid’s symptoms can be tricky to distinguish from a cold or flu, especially now that vaccines and years of infections have ...